Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second neoplasms in acute lymphoblastic leukemia.

M H Zarrabi, F Rosner, H W Grünwald

    Cancer
    |November 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Genetic aspects for the behaviour of lactating sows towards humans.

    Animal : an international journal of animal bioscience·2022
    Same author

    The efficacy of prayer: Scientific vs religious evidence.

    Journal of religion and health·2014
    Same author

    The Jewish patient in a non-Jewish hospital.

    Journal of religion and health·2013
    Same author

    Non-destructive estimation of the intramuscular fat content of the longissimus muscle of pigs by means of spectral analysis of ultrasound echo signals.

    Meat science·2011
    Same author

    [Not Available].

    Year book·2011
    Same author

    Hidradenitis suppurativa complicated by erosive arthropathy and ulcerative keratitis.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
    Same journal

    Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

    Cancer·2026
    Same journal

    Bendamustine in indolent lymphoma: Letting the dust settle down.

    Cancer·2026
    Same journal

    Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.

    Cancer·2026
    Same journal

    Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.

    Cancer·2026
    Same journal

    Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

    Cancer·2026
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    See all related articles

    Intensive treatment for acute lymphoblastic leukemia (ALL) shows no clear link to therapy-related second neoplasms. More research is needed to confirm if ALL survivors face a higher risk of developing acute myeloblastic leukemia.

    Area of Science:

    • Hematology
    • Oncology
    • Cancer Research

    Background:

    • Acute lymphoblastic leukemia (ALL) is a common cancer in children and adults.
    • Intensive treatments like chemotherapy and radiotherapy are used for ALL.
    • The risk of developing secondary cancers after ALL treatment is a concern.

    Purpose of the Study:

    • To investigate the occurrence of second neoplasms in patients previously treated for ALL.
    • To determine if intensive ALL therapy increases the risk of secondary malignancies.
    • To assess the frequency of acute myeloblastic leukemia as a second neoplasm after ALL.

    Main Methods:

    • A literature review of 61 reported cases of second neoplasms in patients with a history of ALL.
    • Categorization of second neoplasms into acute leukemia, chronic myelocytic leukemia, lymphoma, and solid tumors.

    Related Experiment Videos

  • Analysis of the relationship between ALL treatment intensity and the development of second neoplasms.

    • Main Results:

    • The review identified various second neoplasms following ALL treatment, including acute leukemia, chronic myelocytic leukemia, lymphoma, and solid tumors.
    • Currently, there is no definitive evidence linking intensive chemotherapy and/or radiotherapy for ALL to an increased risk of therapy-related second neoplasms.
    • The reported cases are too few to establish if acute myeloblastic leukemia occurs more frequently than expected after intensive ALL therapy.

    Conclusions:

    • Existing data do not strongly support an increased risk of second neoplasms after intensive ALL treatment.
    • Further research with larger case numbers is required to definitively assess the risk of specific second neoplasms, such as acute myeloblastic leukemia, post-ALL therapy.